138
Views
21
CrossRef citations to date
0
Altmetric
Vaccine Profile

Development of Peru-15 (CholeraGarde®), a live-attenuated oral cholera vaccine: 1991–2009

, &
Pages 1643-1652 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Hyesuk Seo, Qiangde Duan & Weiping Zhang. (2020) Vaccines against gastroenteritis, current progress and challenges. Gut Microbes 11:6, pages 1486-1517.
Read now
Amit Saha, Alexander Rosewell, Andrew Hayen, C. Raina MacIntyre & Firdausi Qadri. (2017) Improving immunization approaches to cholera. Expert Review of Vaccines 16:3, pages 235-248.
Read now
Chandrika Murugaiah. (2011) The burden of cholera. Critical Reviews in Microbiology 37:4, pages 337-348.
Read now
Anne L Bishop & Andrew Camilli. (2011) Vibrio cholerae: lessons for mucosal vaccine design. Expert Review of Vaccines 10:1, pages 79-94.
Read now

Articles from other publishers (17)

Brandon Sit, Bolutife Fakoya & Matthew K. Waldor. (2022) Emerging Concepts in Cholera Vaccine Design. Annual Review of Microbiology 76:1, pages 681-702.
Crossref
Tew Hui Xian, Kurunathan Sinniah, Chan Yean Yean, Venkateskumar Krishnamoorthy, Mohd Baidi Bahari, Manickam Ravichandran & Guruswamy Prabhakaran. (2020) Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days. BMC Immunology 21:1.
Crossref
W. Ratanasuwan, Y.H. Kim, B.K. Sah, S. Suwanagool, D.R. Kim, A. Anekthananon, A.L. Lopez, W. Techasathit, S.L. Grahek, J.D. Clemens & T.F. Wierzba. (2015) Peru-15 (Choleragarde®), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand. Vaccine 33:38, pages 4820-4826.
Crossref
Anita H. J. van den Biggelaar & Jan T. Poolman. 2015. Vaccine Analysis: Strategies, Principles, and Control. Vaccine Analysis: Strategies, Principles, and Control 139 186 .
Tatsuhiko Azegami, Yoshikazu Yuki & Hiroshi Kiyono. (2014) Challenges in mucosal vaccines for the control of infectious diseases. International Immunology 26:9, pages 517-528.
Crossref
Rudra Chhajer & Nahid Ali. (2014) Genetically Modified Organisms and Visceral Leishmaniasis. Frontiers in Immunology 5.
Crossref
L. von Seidlein, M. Jiddawi, R. F. Grais, F. Luquero, M. Lucas & J. Deen. (2013) The Value of and Challenges for Cholera Vaccines in Africa. Journal of Infectious Diseases 208:suppl 1, pages S8-S14.
Crossref
M. Pastor, J.L. Pedraz & A. Esquisabel. (2013) The state-of-the-art of approved and under-development cholera vaccines. Vaccine 31:38, pages 4069-4078.
Crossref
Firdausi Qadri, Taufiqur Rahman Bhuiyan, David A. Sack & Ann-Mari Svennerholm. (2013) Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine 31:3, pages 452-460.
Crossref
Paul Erlich & Philippe J. Sansonetti. (2013) Infections intestinales aiguës : vaccins actuels et futurs. La Presse Médicale 42:1, pages 93-101.
Crossref
Luther A. Bartelt & Richard L. Guerrant. 2013. Challenges in Infectious Diseases. Challenges in Infectious Diseases 147 202 .
Meghan Muse, Cyrille Grandjean, Terri K. Wade & William F. Wade. (2012) A one dose experimental cholera vaccine. FEMS Immunology & Medical Microbiology 66:1, pages 98-115.
Crossref
Sachin N. Desai & John D. Clemens. (2012) An overview of cholera vaccines and their public health implications. Current Opinion in Pediatrics 24:1, pages 85-91.
Crossref
Richelle C. Charles & Edward T. Ryan. (2011) Cholera in the 21st century. Current Opinion in Infectious Diseases 24:5, pages 472-477.
Crossref
Joseph G. Sinkovics. 2011. Cell Fusion in Health and Disease. Cell Fusion in Health and Disease 5 89 .
D. Ewen Cameron & John J. Mekalanos. 2011. Replicating Vaccines. Replicating Vaccines 261 281 .
Haopeng Rui, Jennifer M. RitchieRoderick T. BronsonJohn J. MekalanosYuanxing Zhang & Matthew K. Waldor. (2010) Reactogenicity of live-attenuated Vibrio cholerae vaccines is dependent on flagellins . Proceedings of the National Academy of Sciences 107:9, pages 4359-4364.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.